S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
OTCMKTS:CTTC

Calmare Therapeutics - CTTC Stock Forecast, Price & News

$0.0002
0.00 (0.00%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range
$0.00
$0.05
52-Week Range
$0.00
$0.03
Volume
N/A
Average Volume
2,900 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CTTC stock logo

About Calmare Therapeutics (OTCMKTS:CTTC) Stock

Calmare Therapeutics, Inc. engages in the research, development, and commercialization of chronic, neuropathic pain and wound affliction devices. It offers licensing and technology sourcing. The company was founded in 1968 and is headquartered in Fairfield, CT.

Receive CTTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calmare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTTC Stock News Headlines

Calmare Therapeutics Inc (CTTC)
Calmare Therapeutics Inc.
News for Calmare Therapeutics Inc
Calmare Therapeutics Inc
Calmare Therapeutics Incorporated (CTTC)
Calmare Therapeutics CEO Issues Statement
See More Headlines
Receive CTTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calmare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTTC Company Calendar

Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CTTC
Employees
7
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-0.29

Key Executives

  • Conrad F. Mir
    President, Chief Executive Officer & Director
  • Thomas P. Richtarich
    Chief Financial Officer
  • Stephen J. D'Amato
    Chief Medical Officer
  • Donna J. Mays
    Manager-Administrative Services
  • William Lipford
    Head-Product Sales













CTTC Stock - Frequently Asked Questions

How has Calmare Therapeutics' stock price performed in 2022?

Calmare Therapeutics' stock was trading at $0.0001 on January 1st, 2022. Since then, CTTC shares have increased by 100.0% and is now trading at $0.0002.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Calmare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calmare Therapeutics investors own include Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI), Costco Wholesale (COST), Blue Apron (APRN), Arista Networks (ANET), Amgen (AMGN), Advanced Micro Devices (AMD), Akers Biosciences (AKER) and AdvisorShares Vice ETF (ACT).

What is Calmare Therapeutics' stock symbol?

Calmare Therapeutics trades on the OTCMKTS under the ticker symbol "CTTC."

How do I buy shares of Calmare Therapeutics?

Shares of CTTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calmare Therapeutics' stock price today?

One share of CTTC stock can currently be purchased for approximately $0.00.

How many employees does Calmare Therapeutics have?

Calmare Therapeutics employs 7 workers across the globe.

How can I contact Calmare Therapeutics?

Calmare Therapeutics' mailing address is 1375 KINGS HIGHWAY EAST SUITE 400, FAIRFIELD CT, 06824. The official website for the company is www.calmaretherapeutics.com. The company can be reached via phone at (203) 368-6044, via email at ctt@calmaretherapeutics.com, or via fax at 203-368-5399.

This page (OTCMKTS:CTTC) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.